macdonald-epcamimmunotherapy-2018.pdf (1.78 MB)
EpCAM immunotherapy versus specific targeted delivery of drugs
journal contribution
posted on 2018-01-12, 00:00 authored by Joanna Michelle Macdonald, Justin Liam Henri, Kislay Roy, Emma Hays, Michelle BauerMichelle Bauer, Rakesh Naduvile Veedu, Normand Pouliot, Sarah ShigdarSarah ShigdarThe epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy.
History
Journal
CancersVolume
10Issue
1Pagination
1 - 13Publisher
MDPILocation
Basel, SwitzerlandPublisher DOI
Link to full text
ISSN
2072-6694Language
engPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2018, The AuthorsUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC